6-1-1 | | | | 一、审计报告 … | | --- | | 二、财务报表 ……………………………………………………………… 第 7-14 页 | | (一) 合并资产负债表 | | (二)母公司资产负债表 ……………………………………………………… 第 8 页 | | (三) 合并利润表………………………………………………………………………………………………………… 第 9 页 | | (四)母公司利润表 | | (五) 合并现金流量表………………………………………………………第 11 页 | | (六) 母公司现金流量表 ………………………………………… 第 12 页 | | (七) 合并所有者权益变动表 … | | (八)母公司所有者权益变动表 … | | 三、财务报表附注 …………………………………………………………… 第 15-92 页 | | --- | 6-1-2 天健审〔2023〕818号 浙江圣达生物药业股份有限公司全体股东: 一、审计意见 我们审计了浙江圣达生物药业股份有限公司(以下简称圣达生物公司)财务 报表,包括2022年12月31日的合并及母公司资产负债表,2022年度的合并 ...

中信建投证券股份有限公司 关于 浙江圣达生物药业股份有限公司 向特定对象发行股票 之 发行保荐书 保荐人 二〇二三年八月 保荐人出具的证券发行保荐书 保荐人及保荐代表人声明 中信建投证券股份有限公司及本项目保荐代表人王站、王书言根据《中华 人民共和国公司法》《中华人民共和国证券法》等有关法律、法规和中国证监会 的有关规定以及上海证券交易所的有关业务规则，诚实守信，勤勉尽责，严格 按照依法制订的业务规则、行业执业规范和道德准则出具本发行保荐书，并保 证发行保荐书的真实性、准确性和完整性。 | 释 义 | 2 | | --- | --- | | 第一节 本次证券发行基本情况 | 4 | | 一、本次证券发行具体负责推荐的保荐代表人 4 | | | 二、本次证券发行项目协办人及项目组其他成员 4 | | | 三、发行人基本情况 5 | | | 四、保荐人与发行人关联关系的说明 8 | | | 五、保荐人内部审核程序和内核意见 9 | | | 六、保荐人对私募投资基金备案情况的核查 10 | | | 第二节 保荐人承诺事项 | 12 | | 第三节 | 关于有偿聘请第三方机构和个人等相关行为的核查 13 | | 一、 ...

向特定对象发行股票 证券简称：圣达生物 证券代码：603079 浙江圣达生物药业股份有限公司 ZHEJIANG SHENGDA BIO-PHARM CO., LTD. （浙江省天台县赤城街道人民东路789号） 二〇二三年八月 圣达生物向特定对象发行股票 募集说明书 声 明 募集说明书 （申报稿） 保荐人（主承销商） （北京市朝阳区安立路66号4号楼） 中国证监会、上海证券交易所对本次发行所作的任何决定或意见，均不表明 其对申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对 发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何 与之相反的声明均属虚假不实陈述。 根据《证券法》规定，证券依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 证券依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 投资者若对本募集说明书存在任何疑问，应咨询自己的股票经纪人、律师、 会计师或其他专业顾问。 1-1-1 圣达生物向特定对象发行股票 募集说明书 重大事项提示 公司特别提请投资者注意，在作出投资决策之前，务必仔细阅读 ...

获得上海证券交易所受理的公告 公司本次向特定对象发行股票事项尚需上交所审核通过及中国证券监督管 理委员会（以下简称"中国证监会"）作出同意注册决定后方可实施，最终能 否通过上交所审核，并获得中国证监会同意注册的决定及其时间尚存在不确定 性。公司将根据该事项的进展情况及时履行信息披露义务，敬请广大投资者注 意投资风险。 特此公告。 浙江圣达生物药业股份有限公司董事会 2023年8月16日 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603079 证券简称：圣达生物 公告编号：2023-035 浙江圣达生物药业股份有限公司（以下简称"公司"）于2023年8月15日收 到上海证券交易所（以下简称"上交所"）出具的《关于受理浙江圣达生物药 业股份有限公司沪市主板上市公司发行证券申请的通知》（上证上审（再融资 ）〔2023〕580号），上交所依据相关规定对公司报送的沪市主板上市公司发行 证券的募集说明书及相关申请文件进行了核对，认为该项申请文件齐备，符合 法定形式，决定予以受理并依法进行审核。 浙江圣达生物药业股份有限公司 ...

中信建投证券股份有限公司 关于 浙江圣达生物药业股份有限公司 向特定对象发行股票 之 上市保荐书 保荐人 二〇二三年八月 保荐人出具的上市保荐书 保荐人及保荐代表人声明 中信建投证券股份有限公司及本项目保荐代表人王站、王书言已根据《中 华人民共和国公司法》《中华人民共和国证券法》等法律法规和中国证监会及上 海证券交易所的有关规定，诚实守信，勤勉尽责，严格按照依法制定的业务规 则和行业自律规范出具上市保荐书，并保证所出具文件真实、准确、完整。 保荐人出具的上市保荐书 释 义 在本上市保荐书中，除非另有说明，下列词语具有如下特定含义 | 保荐人/中信建投证券 | 指 | 中信建投证券股份有限公司 | | --- | --- | --- | | 圣达生物/发行人/公司 | 指 | 浙江圣达生物药业股份有限公司 | | 本上市保荐书 | 指 | 中信建投证券股份有限公司关于浙江圣达生物药业股份 | | | | 有限公司向特定对象发行股票之上市保荐书 | | 股东大会 | 指 | 浙江圣达生物药业股份有限公司股东大会 | | 董事会 | 指 | 浙江圣达生物药业股份有限公司董事会 | | 人民币普通股、A股 | 指 | ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥169,278,694.33, representing a decrease of 8.58% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥3,491,046.45, down 83.22% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥768,830.17, a decline of 105.34%[5]. - The basic and diluted earnings per share were both ¥0.02, reflecting a decrease of 83.33%[6]. - The net profit for Q1 2023 was CNY 3,271,632.91, a significant decrease of 84.0% compared to CNY 20,395,348.28 in Q1 2022[22]. - The company achieved a total profit of CNY 5,575,375.89, down from CNY 23,676,663.82 in the same quarter last year[22]. - The company reported a net profit margin of approximately 0.75% for Q1 2023, compared to 9.0% in Q1 2022, indicating a decline in profitability[20]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥49,775,808.03, indicating a significant cash outflow[6]. - The company reported a net cash outflow from operating activities of CNY -49,775,808.03, worsening from CNY -11,335,230.05 in Q1 2022[24]. - Cash and cash equivalents as of March 31, 2023, were RMB 279,068,031.81, down from RMB 320,717,851.36 at the end of 2022, representing a decrease of 12.9%[17]. - Cash and cash equivalents at the end of Q1 2023 were CNY 260,029,482.88, down from CNY 296,238,667.03 at the end of Q1 2022[25]. - Investment activities resulted in a net cash outflow of CNY -57,724,177.90, compared to CNY -182,830,411.59 in Q1 2022[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,615,005,744.91, down 2.43% from the end of the previous year[6]. - Total assets as of March 31, 2023, were RMB 1,615,005,744.91, down from RMB 1,655,207,544.77 at the end of 2022, a decrease of 2.4%[19]. - Total liabilities decreased to RMB 268,288,501.34 from RMB 311,761,934.11, a reduction of 13.9%[19]. - The company's equity attributable to shareholders increased slightly to RMB 1,331,488,386.18 from RMB 1,327,997,339.73, an increase of 0.1%[19]. - Short-term borrowings were reduced to RMB 10,007,300.00 from RMB 32,642,669.33, a significant decrease of 69.4%[18]. Operating Costs and Expenses - Total operating costs for Q1 2023 were RMB 168,012,041.08, slightly up from RMB 167,206,511.12 in Q1 2022, indicating a marginal increase of 0.5%[20]. - The company incurred a total operating expense of CNY 230,012,747.88, an increase from CNY 196,570,365.22 in the previous year[24]. - Research and development expenses increased to CNY 9,192,182.34, up 27.7% from CNY 7,196,029.08 in Q1 2022[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,547[12]. - The company received government subsidies amounting to ¥4,235,086.52, which were included in the current period's profit[9]. Market Conditions - The decline in net profit was primarily due to the continuous decrease in vitamin product prices and rising raw material costs[10].

Financial Performance - The company achieved a net profit of CNY 5,913,119.37 in 2022, with a distributable profit of CNY 321,336,147.48 after statutory reserve and previous undistributed profits adjustments[7]. - The company's operating revenue for 2022 was RMB 738,019,050.08, a decrease of 6.55% compared to RMB 789,732,754.87 in 2021[25]. - The net profit attributable to shareholders for 2022 was RMB 31,486,120.69, down 58.44% from RMB 75,756,473.97 in the previous year[25]. - The basic earnings per share for 2022 was RMB 0.18, a decline of 59.09% from RMB 0.44 in 2021[27]. - The cash flow from operating activities for 2022 was RMB 40,717,546.99, a decrease of 45.32% compared to RMB 74,460,439.98 in 2021[25]. - The total assets at the end of 2022 were RMB 1,655,207,544.77, a decrease of 6.21% from RMB 1,764,814,096.10 at the end of 2021[26]. - The weighted average return on equity for 2022 was 2.38%, down 3.41 percentage points from 5.79% in 2021[27]. - The net profit after deducting non-recurring gains and losses for 2022 was RMB 10,691,488.19, a decrease of 79.25% from RMB 51,524,494.20 in 2021[25]. - The company reported a significant increase in financial expenses due to a rise in exchange gains, with a net financial expense of CNY -21.88 million, compared to CNY 8.87 million in the previous year[59]. Dividend Policy - A cash dividend of CNY 0.60 per 10 shares (including tax) is proposed for distribution to shareholders, pending approval at the 2022 annual general meeting[7]. - The company has outlined a three-year shareholder dividend return plan, aligning with regulatory requirements and long-term development needs[7]. - The total cash dividend amount for the reporting period was 10,271,337.48 RMB, representing 32.62% of the net profit attributable to ordinary shareholders[159]. Risks and Challenges - The company faces significant risks including product price fluctuations, raw material price volatility, high customer concentration, exchange rate fluctuations, and changes in the macroeconomic environment[11]. - The company experienced a significant decline in sales revenue due to a drop in the price of its main product, biotin[27]. - The company has a high customer concentration risk, with the top five customers accounting for 21.09% of revenue in 2022[122]. - The company’s export revenue constituted 39.48% of its main business income in 2022, exposing it to exchange rate risks[122]. - Raw material price fluctuations significantly impact the company's profitability, as raw materials constitute a large portion of production costs[121]. Operational Highlights - The company has a 75% stake in Tongliao Shengda, a key subsidiary, which contributes to its operational capabilities[15]. - The company maintained a leading market share in its main products despite a challenging market environment[37]. - The subsidiary XinYinXiang achieved a sales growth of 18.53% and a net profit increase of 1.36% compared to the previous year[38]. - The company implemented cost reduction measures, achieving over 10% reduction in raw material procurement costs through innovative projects[38]. - The clean label product segment saw a significant revenue increase of 139.17%[37]. Research and Development - The company continues to invest in R&D, focusing on green catalytic technology and synthetic biology to enhance its technological capabilities[40]. - The company invested a total of RMB 37.81 million in R&D during the reporting period, with 28 ongoing projects and 5 national patents granted, including 4 invention patents[89]. - The number of R&D personnel is 160, accounting for 13.89% of the total workforce[74]. Governance and Compliance - The company emphasizes the importance of maintaining the authenticity and completeness of its financial reports, as confirmed by Tianjian Accounting Firm's standard unqualified audit report[6]. - The board of directors and supervisory board members have all attended the board meeting, ensuring governance compliance[5]. - The company has established a fair and transparent performance evaluation and incentive mechanism for directors and senior management, ensuring compliance with relevant laws and regulations[131]. - The company has maintained a governance structure that respects and protects the legitimate rights and interests of stakeholders, balancing the interests of shareholders, employees, and society[127]. Environmental Performance - The company reported a significant reduction in wastewater emissions from 307,509.938 tons in 2021 to 132,395 tons in 2022, indicating improved environmental performance[165]. - The company’s solid waste generation decreased from 990.81 tons in 2021 to 430.73 tons in 2022, reflecting enhanced waste management practices[165]. - The company maintains a daily wastewater treatment capacity of 520 tons, ensuring compliance with environmental standards[165]. - The company has established an environmental management system certified by ISO14001, ensuring stable operation of pollution control facilities[185]. Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion[132]. - The company plans to invest RMB 499.87 million in the first phase of the vitamin series products and raw materials upgrade project, expected to produce 220 tons of biotin and 1,000 tons of folic acid annually upon completion[99]. - The company aims to enhance product reserves and expand product applications through technological innovation and collaboration with research institutions[117]. - The company plans to enhance its market presence by expanding its environmental services to new regions and sectors[176].

证券代码：603079 证券简称：圣达生物 公告编号：2023-020 浙江圣达生物药业股份有限公司 关于召开2022年度业绩说明会的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 04 月 25 日（星期二）下午 13:00-14:00 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow. sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 18 日(星期二)至 04 月 24 日(星期一)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zqb@sd- pharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 浙江圣达生物药业股份有限公司（以下简称"公司"）已于 2023 年 03 月 25 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年 度经营成果、财务状况，公司计划于 2023 年 04 月 25 日下午 13 ...

Financial Performance - The company reported a net profit of CNY 5,913,119.37 for the year 2022, with a proposed cash dividend of CNY 0.60 per share[7]. - The total distributable profit for shareholders after accounting for legal reserves and previous undistributed profits is CNY 321,336,147.48[7]. - The company plans to allocate 10% of the net profit to statutory surplus reserves, amounting to CNY 591,311.94[7]. - The company's operating revenue for 2022 was RMB 738,019,050.08, a decrease of 6.55% compared to RMB 789,732,754.87 in 2021[25]. - The net profit attributable to shareholders for 2022 was RMB 31,486,120.69, down 58.44% from RMB 75,756,473.97 in the previous year[25]. - The basic earnings per share for 2022 was RMB 0.18, reflecting a decline of 59.09% from RMB 0.44 in 2021[27]. - The cash flow from operating activities for 2022 was RMB 40,717,546.99, a decrease of 45.32% compared to RMB 74,460,439.98 in 2021[25]. - The total assets at the end of 2022 were RMB 1,655,207,544.77, down 6.21% from RMB 1,764,814,096.10 at the end of 2021[26]. - The weighted average return on equity for 2022 was 2.38%, a decrease of 3.41 percentage points from 5.79% in 2021[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 10,691,488.19, down 79.25% from RMB 51,524,494.20 in 2021[25]. Risks and Challenges - The company faces significant risks including product price fluctuations, raw material price volatility, and high customer concentration risk[11]. - The company experienced a significant drop in sales revenue due to a decrease in the price of its main product, biotin[27]. - Sales revenue from the top five customers accounted for 21.09% of total revenue in 2022, indicating a high customer concentration risk[122]. - The company's export revenue represented 39.48% of main business income in 2022, exposing it to foreign exchange risk due to reliance on USD for transactions[122]. - The vitamin industry is facing competitive pressure due to oversupply, but the company is positioned to leverage potential opportunities in 2023[42]. Subsidiaries and Investments - The company has a 75% stake in its subsidiary, Tongliao Shengda, which is a key part of its operations[15]. - The subsidiary XinYinXiang achieved a sales increase of 18.53% and a net profit growth of 1.36% compared to the previous year[38]. - The company’s subsidiary, New Silver Elephant, reported a revenue of 350.06 million RMB and a net profit of 35.78 million RMB in 2022[115]. - The company has a diverse portfolio of subsidiaries and associated companies, enhancing its market presence and operational capabilities[135]. Research and Development - The company is actively engaged in research and development, focusing on green catalytic technology and synthetic biology to support product development and technical support[40]. - The company invested CNY 37,810,800 in R&D during the reporting period, with 28 ongoing projects and 5 patents granted, including 4 invention patents[89]. - The company holds 5 national authorized patents, including 4 invention patents, reflecting its commitment to R&D and innovation[57]. - The company has established a strong talent development system, completing the introduction of four high-level talents at the national and provincial levels in 2022[40]. Environmental Performance - The company reported a significant reduction in wastewater emissions from 307,509.938 tons in 2021 to 132,395 tons in 2022, indicating improved environmental performance[165]. - The company maintained compliance with environmental standards for air emissions, with all reported pollutants meeting regulatory requirements[165]. - The company’s solid waste generation included 990.81 tons of distillation residues and 8,227 tons of sludge in 2022, reflecting ongoing waste management efforts[165]. - The company has established a dedicated environmental management department to oversee pollution prevention and compliance with environmental regulations[185]. - The company has implemented energy-saving measures and is actively managing carbon emissions, including the use of heat recovery technology[186]. Governance and Compliance - The company emphasizes the importance of maintaining the accuracy and completeness of its financial reports, as confirmed by its auditing firm[6]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[9]. - The company has not faced any violations in decision-making procedures regarding external guarantees[9]. - The company has established a transparent performance evaluation and incentive mechanism for its senior management[127]. - The company held three shareholder meetings in 2022, approving a total of 16 proposals, including the annual report for 2021 and the allocation of surplus funds for liquidity[129]. Market Strategy and Future Plans - The company is committed to long-term development while balancing immediate shareholder interests in its profit distribution plan[7]. - The company plans to invest approximately RMB 499.87 million in the first phase of the vitamin series product and raw material drug industry upgrade project, with an expected annual production of 220 tons of biotin and 1,000 tons of folic acid upon completion[99]. - The company aims to enhance production capacity for biological preservatives due to high demand, which has led to the abandonment of some clients[116]. - The company plans to strengthen its position in the synthetic biology industry by gradually expanding its technology base[118]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 150 million allocated for potential deals[132].

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with total revenue reaching 500 million RMB, representing a 20% year-over-year growth[11]. - The company's operating revenue for the first half of 2022 was ¥350,441,523.13, a decrease of 10.17% compared to ¥390,135,440.81 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2022 was ¥39,932,027.45, down 16.62% from ¥47,889,762.29 year-on-year[19]. - The basic earnings per share for the first half of 2022 was ¥0.23, a decline of 17.86% from ¥0.28 in the same period last year[20]. - The company reported a significant decline in sales volume of vitamin products, leading to reduced revenue and profit metrics[21]. - The company reported a net loss of CNY 59.92 million for the period, indicating a significant decrease in profitability[183]. Market Expansion and Product Development - The company has provided a positive outlook for the second half of 2022, projecting a revenue growth of 25% based on new product launches and market expansion strategies[11]. - Research and development efforts have led to the introduction of two new products in the biopharmaceutical sector, expected to contribute an additional 50 million RMB in revenue[11]. - The company is actively pursuing market expansion, targeting a 30% increase in market share in the next fiscal year through strategic partnerships and collaborations[11]. - The company is focusing on R&D innovation and expanding its product application areas to enhance customer loyalty and market competitiveness[32]. - The company plans to focus on market expansion and new product development in the upcoming quarters[162]. Financial Position and Cash Flow - The company has committed to maintaining a strong cash position, with cash reserves of 200 million RMB, ensuring liquidity for future investments[11]. - The net cash flow from operating activities decreased by 45.44% to ¥28,477,144.10, compared to ¥52,191,787.85 in the previous year[19]. - Cash and cash equivalents decreased significantly from ¥514,747,873.78 to ¥278,152,903.15, reflecting a decline of approximately 46%[155]. - The total cash and cash equivalents at the end of the period were CNY 252,806,779.74, down from CNY 348,596,797.29 at the end of the first half of 2021, reflecting a decrease of approximately 27.4%[171]. Research and Development - The company continues to focus on the research and development of biotin and biopreservation agents, maintaining its position as a major supplier in the global market[26]. - R&D investment increased by 1.72% year-on-year, emphasizing the company's commitment to innovation and technology development[45]. - The company has received 2 national invention patents and applied for 2 additional invention patents during the reporting period[40]. Environmental Compliance and Sustainability - The company has implemented a digital transformation in its procurement management through the introduction of ERP and BI systems, enhancing cost management[31]. - The company is actively promoting a green circular economy model, focusing on the reuse of by-products and continuous technological innovation[44]. - The company has established a commitment to protect investor interests, ensuring no misleading information in its IPO prospectus[96]. - The company has committed to continuous improvement in its environmental management practices[88]. Risk Management - The company faces risks including price fluctuations in raw materials, which could impact profit margins by up to 10% if not managed effectively[5]. - The management has emphasized the importance of diversifying the supply chain to mitigate risks associated with high customer concentration, which currently stands at 60%[5]. - The company has taken steps to reduce the impact of raw material price fluctuations on its operating performance through various operational strategies[61]. Shareholder Commitments and Governance - The company has committed to long-term shareholding intentions, with plans to gradually reduce holdings only after the lock-up period, adhering to regulatory requirements[95]. - The company guarantees that it and its controlled entities will not engage in any business that competes with its subsidiaries, both domestically and internationally[100]. - The company will publicly disclose reasons for any failure to fulfill commitments and will not engage in public refinancing during such periods[125].